Literature DB >> 15908442

Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70.

Mark R Nelson1, Danny Liew, Melanie Bertram, Theo Vos.   

Abstract

OBJECTIVE: To investigate the routine use of low dose aspirin in people aged > or = 70 without overt cardiovascular disease.
DESIGN: Epidemiological modelling in a hypothetical population.
SETTING: Reference populations of men and women in the year 2000 from the state of Victoria, Australia.
SUBJECTS: 10,000 men and 10,000 women aged 70-74 with no cardiovascular disease. MAIN OUTCOME MEASURES: First ever myocardial infarction or unstable angina, ischaemic or haemorrhagic stroke, and major gastrointestinal haemorrhage. Health adjusted years of life lived.
RESULTS: The proportional benefit gained from the use of low dose aspirin by the prevention of myocardial infarctions (-389 in men, -321 in women) and ischaemic stroke (-19 in men and -35 in women) is offset by excess gastrointestinal (499 in men, 572 in women) and intracranial (76 in men, 54 in women) bleeding. The results in health adjusted years of life lived (which take into account length and quality of life) are equivocal for aspirin causing net harm or net benefit.
CONCLUSION: Epidemiological modelling suggests that any benefits of low dose aspirin on risk of cardiovascular disease in people aged > or = 70 are offset by adverse events. These findings are tempered by wide confidence intervals, indicating that the overall outcome could be beneficial or adverse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908442      PMCID: PMC558207          DOI: 10.1136/bmj.38456.676806.8F

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

Review 1.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

2.  Aspirin use and cognitive function in the elderly.

Authors:  T Stürmer; R J Glynn; T S Field; J O Taylor; C H Hennekens
Journal:  Am J Epidemiol       Date:  1996-04-01       Impact factor: 4.897

Review 3.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

Review 4.  Decision analysis and the implementation of research findings.

Authors:  R J Lilford; S G Pauker; D A Braunholtz; J Chard
Journal:  BMJ       Date:  1998-08-08

Review 5.  Nonsteroidal anti-inflammatory drugs and cancer prevention.

Authors:  J A Baron; R S Sandler
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

6.  Stroke incidence on the east coast of Australia: the North East Melbourne Stroke Incidence Study (NEMESIS).

Authors:  A G Thrift; H M Dewey; R A Macdonell; J J McNeil; G A Donnan
Journal:  Stroke       Date:  2000-09       Impact factor: 7.914

7.  Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.

Authors:  R G Hart; J L Halperin; R McBride; O Benavente; M Man-Son-Hing; R A Kronmal
Journal:  Arch Neurol       Date:  2000-03

8.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

9.  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.

Authors:  Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  9 in total

1.  Aspirin as a Potential Geroprotector: Experimental Data and Clinical Evidence.

Authors:  Oleh Lushchak; Veronika Piskovatska; Olha Strilbytska; Iryna Kindrat; Nadya Stefanyshyn; Alexander Koliada; Volodymyr Bubalo; Kenneth B Storey; Alexander Vaiserman
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Citizen jury should consider aspirin prophylaxis.

Authors:  Rachel T Iredale
Journal:  BMJ       Date:  2005-07-16

3.  Prophylactic use of gastro-protective agents in patients on low-dose aspirin.

Authors:  S Balakrishnan; R Jhaj
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

4.  Predicting the effectiveness of prevention: a role for epidemiological modeling.

Authors:  Helen L Walls; Anna Peeters; Christopher M Reid; Danny Liew; John J McNeil
Journal:  J Prim Prev       Date:  2008-07

5.  Separate prediction of intracerebral hemorrhage and ischemic stroke.

Authors:  Bart S Ferket; Bob J H van Kempen; Renske G Wieberdink; Ewout W Steyerberg; Peter J Koudstaal; Albert Hofman; Eyal Shahar; Rebecca F Gottesman; Wayne Rosamond; Jorge R Kizer; Richard A Kronmal; Bruce M Psaty; W T Longstreth; Thomas Mosley; Aaron R Folsom; M G Myriam Hunink; M Arfan Ikram
Journal:  Neurology       Date:  2014-04-23       Impact factor: 9.910

Review 6.  Aspirin for primary prevention of cardiovascular events in the elderly: current status and future directions.

Authors:  Stephanie A Ward; Lisa Demos; Barbara Workman; John J McNeil
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 7.  Pain management today - what have we learned?

Authors:  Richard M Langford
Journal:  Clin Rheumatol       Date:  2006-06-02       Impact factor: 2.980

Review 8.  Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?

Authors:  Caroline Sirois; Julie Couture; Jean-Pierre Grégoire
Journal:  Ther Adv Drug Saf       Date:  2012-10

9.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Authors:  John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.